Inhibrx Inc company info

What does Inhibrx Inc do?
Inhibrx (NASDAQ:INBX), a biotechnology company, is dedicated to the discovery, development, and commercialization of novel therapeutics for the treatment of cancer, infectious diseases, and inflammatory conditions. This commitment is underpinned by its versatile platform and a broad pipeline, including lead programs like INBRX-101 for AATD and INBRX-109 for chondrosarcoma. With a focused approach to leveraging its proprietary technologies, Inhibrx aims to bring innovative solutions to areas of high unmet medical need. The company’s objective centers on advancing these promising therapeutic candidates through clinical trials to ultimately improve patient outcomes across various diseases.
Inhibrx Inc company media
Company Snapshot

Is Inhibrx Inc a public or private company?

key
Ownership
Public

How many people does Inhibrx Inc employ?

people
Employees
156

What sector is Inhibrx Inc in?

pie chart
Sector
Health Care

Where is the head office for Inhibrx Inc?

location pin
Head Office
California, United States

What year was Inhibrx Inc founded?

founded flag
Year Founded
2010
What does Inhibrx Inc specialise in?
/Therapeutic Antibodies /Oncology Treatments /Protein Engineering /Respiratory Therapies /Orphan Diseases /Clinical Trials

What are the products and/or services of Inhibrx Inc?

Overview of Inhibrx Inc offerings
A therapy targeting CD47 to enable the immune system to combat cancer and other serious diseases more effectively.
An antibody aimed at treating various solid tumor types through precise targeting of the 4-1BB pathway, enhancing tumor-specific T-cell activity.
A treatment designed for patients with chondrosarcoma, utilizing a proprietary approach to target and inhibit specific cancer growth pathways.
A novel therapy focused on addressing the unmet medical needs in patients with pancreatic cancer, employing targeted mechanisms to halt tumor progression.
Innovative bi-specific antibodies intended to selectively direct the immune system towards cancer cells, minimizing damage to healthy tissues.
Advanced therapeutic options for the treatment of non-small cell lung cancer, leveraging cutting-edge science to disrupt cancer cell growth and survival.

Who is in the executive team of Inhibrx Inc?

Inhibrx Inc leadership team
  • Mr. Mark Paul Lappe
    Mr. Mark Paul Lappe
    Founder, Chairman, President & CEO
  • Dr. Brendan P. Eckelman Ph.D.
    Dr. Brendan P. Eckelman Ph.D.
    Founder & Chief Scientific Officer
  • Ms. Kelly Devine Deck B.S., CPA, M.S.
    Ms. Kelly Devine Deck B.S., CPA, M.S.
    Executive VP & CFO
  • Mr. Quinn L. Deveraux
    Mr. Quinn L. Deveraux
    Founder
  • Dr. Ashraf  Amanullah
    Dr. Ashraf Amanullah
    Executive VP & Chief Technical Operations Officer
  • Ms. Leah  Pollema J.D.
    Ms. Leah Pollema J.D.
    VP, Corporate Secretary & General Counsel
  • Dr. Charbel  Helaihel Pharm.D.
    Dr. Charbel Helaihel Pharm.D.
    Vice President of Marketing & Commercial Planning
  • Mr. Jeffrey J. Jensen
    Mr. Jeffrey J. Jensen
    Executive VP & Chief Clinical Operations Officer